Journal article
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
Anna K Nowak, Chris Brown, Michael J Millward, Jenette Creaney, Michael J Byrne, Brett Hughes, Gabriel Kremmidiotis, David C Bibby, Annabell F Leske, Paul LR Mitchell, Nick Pavlakis, Michael Boyer, Martin R Stockler
Lung Cancer | ELSEVIER IRELAND LTD | Published : 2013
Grants
Funding Acknowledgements
The study was funded by Bionomics Ltd.